» Articles » PMID: 22265712

Development and Performance Evaluation of Novel Chemiluminescence Assays for Detection of Anti-PR3 and Anti-MPO Antibodies

Overview
Journal Clin Chim Acta
Specialty Biochemistry
Date 2012 Jan 24
PMID 22265712
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The detection of anti-proteinase 3 (PR3) and anti-myeloperoxidase (MPO) autoantibodies represents a serological hallmark in the diagnosis of small vessel vasculitis such as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). We evaluated novel chemiluminescence assays (CIAs) for PR3- and MPO-ANCA detection and investigated their utility for disease activity monitoring.

Methods: Sera collected from GPA (n=41) and MPA (n=30) patients were tested by QUANTA Lite® PR-3 and MPO ELISAs (INOVA Diagnostics) and by the QUANTA Flash™ PR3 and MPO CIAs (INOVA). Precision and linearity were analyzed following reference guidelines. The recently launched reference sera for PR3-and MPO-ANCA (Centers of Disease Control and prevention, CDC) were used to establish international units for the new assays. Disease activity was determined using the Birmingham Vasculitis Activity Score.

Results: The international standards for PR3-and MPO-ANCA yielded results of 403 CU and 332 CU in the novel CIAs, respectively. The linearity analysis showed linear regression values>0.97 with slopes between 0.96 and 1.04. Total variation obtained from the precision study showed CV% of ≤7.4 for PR3-ANCA and ≤12.8 for MPO-ANCA. Good agreement (Spearman rho ≥ 0.89) was observed between CIA and ELISA. PR3-ANCA determined by CIA, but not by ELISA, was correlated with disease activity. No correlation was found for MPO-ANCA.

Conclusion: The novel PR3- and MPO-ANCA CIAs show good precision, linearity and correlation to ELISA. In addition, PR3-ANCA by CIA show correlation with disease activity.

Citing Articles

Diagnostic Accuracy of IgA Anti-Transglutaminase Assessed by Chemiluminescence: A Systematic Review and Meta-Analysis.

Pjetraj D, Pulvirenti A, Moretti M, Gatti S, Catassi G, Catassi C Nutrients. 2024; 16(15).

PMID: 39125307 PMC: 11314508. DOI: 10.3390/nu16152427.


Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis.

Wunsch E, Norman G, Milkiewicz M, Krawczyk M, Bentow C, Shums Z Aliment Pharmacol Ther. 2020; 53(2):302-313.

PMID: 33159471 PMC: 7821312. DOI: 10.1111/apt.16153.


The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies.

Hou X, Liu J, Wang T, Zhou J, Cui L J Clin Lab Anal. 2020; 35(2):e23615.

PMID: 33034910 PMC: 7891508. DOI: 10.1002/jcla.23615.


Fecal Serine Protease Profiling in Inflammatory Bowel Diseases.

Jablaoui A, Kriaa A, Mkaouar H, Akermi N, Soussou S, Wysocka M Front Cell Infect Microbiol. 2020; 10:21.

PMID: 32117798 PMC: 7011180. DOI: 10.3389/fcimb.2020.00021.


Evaluation of 12 different assays for detecting ANCA in Chinese patients with GPA and MPA: a multicenter study in China.

Zhang W, Zheng Z, Jia R, Li X, Zuo X, Wu L Clin Rheumatol. 2019; 38(12):3477-3483.

PMID: 31414304 DOI: 10.1007/s10067-019-04736-6.